BridgeBio to Participate in May and June Investor Conferences

Rhea-AI Summary

BridgeBio (Nasdaq: BBIO) announced management will participate in investor fireside chats at three healthcare conferences in May–June 2026: BofA Health Care Conference (May 12, 2:20 pm PDT), Jefferies Global Healthcare Conference (June 4, 11:05 am EDT), and Goldman Sachs Global Healthcare Conference (June 9, 8:00 am EDT).

Live webcasts will be available via the company’s Events and Presentations investor page and replays will remain online for 90 days after each event.

News Market Reaction – BBIO

-0.94%

-0.94% Session close to close

In the May 7 session, BBIO declined 0.94%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement outlines BridgeBio’s participation in three major healthcare investor conferences ...

Analysis

This announcement outlines BridgeBio’s participation in three major healthcare investor conferences in May and June, with fireside chats and webcasts available for 90 days. It signals an emphasis on active investor engagement following recent clinical, regulatory, and corporate updates in prior months. Investors may track these events for commentary on pipeline progress, commercial execution, and capital allocation while considering recent insider transactions and the company’s trading position relative to its 52-week range.

Key Figures

BofA conference time: 2:20 pm PDT Jefferies conference time: 11:05 am EDT Goldman Sachs conference time: 8:00 am EDT +5 more

8 metrics

BofA conference time 2:20 pm PDT BofA Securities Health Care Conference 2026 fireside chat on May 12, 2026

Jefferies conference time 11:05 am EDT Jefferies Global Healthcare Conference fireside chat on June 4, 2026

Goldman Sachs conference time 8:00 am EDT Goldman Sachs 47th Annual Global Healthcare Conference on June 9, 2026

Webcast replay window 90 days Replay of the conference webcasts available on BridgeBio’s website

Current price $68.78 Price prior to the conference participation announcement

52-week high $84.94 Upper end of 52-week trading range before this news

52-week low $31.77 Lower end of 52-week trading range before this news

Market capitalization $13,374,599,470 Equity value at latest pre-announcement price

Historical Context

5 past events · Latest: May 04 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
May 04	Clinical data update	Positive	+0.6%	New Phase 3 ATTRibute-CM data presentations at ESC-Heart Failure 2026.
Apr 30	Earnings timing update	Neutral	+0.2%	Announcement of date and time for Q1 2026 results and webcast.
Apr 28	Awareness campaign	Positive	-6.5%	Launch of national ATTR-CM health education campaign featuring high-profile advocates.
Apr 22	Equity compensation	Neutral	-2.2%	Inducement grants of 67,247 RSUs to new employees under existing plan.
Mar 30	Long-term trial data	Positive	-0.5%	Long-term acoramidis data showing large mortality reductions and sustained benefit.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent data- and campaign-related announcements often generated muted or negative price reactions, even when underlying clinical results were positive.

Recent Company History

Over the last few months, BridgeBio has reported multiple clinical and corporate milestones. In late March, long-term acoramidis data through Month 54 showed substantial mortality reductions, yet shares moved only -0.49%. A March 8-K detailed an NDA submission for BBP‑418 backed by a Phase 3 trial meeting all endpoints. April brought equity grants, a national ATTR‑CM education campaign, and new ATTRibute‑CM data, with mixed price reactions including a -6.45% move on April 28. Today’s conference participation notice fits into this steady cadence of investor-engagement and clinical updates.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

PALO ALTO, Calif., May 06, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing medicines for genetic conditions, today announced that members of its management team will participate in fireside chats at the following healthcare investor conferences:

• BofA Securities Health Care Conference 2026, Las Vegas, NV: Tuesday, May 12 at 2:20 pm PDT
• 2026 Jefferies Global Healthcare Conference, New York, NY: Thursday, June 4 at 11:05 am EDT
• Goldman Sachs 47^th Annual Global Healthcare Conference, Miami FL: Tuesday, June 9 at 8:00 am EDT
  
  

To access the live webcast of BridgeBio’s presentations, please visit the “Events and Presentations” page within the Investors section of the BridgeBio website at https://investor.bridgebio.com. A replay of the webcasts will be available on the BridgeBio website for 90 days following the event.

About BridgeBio Pharma, Inc.
BridgeBio exists to develop transformative medicines for genetic conditions. Millions of people worldwide living with genetic conditions lack treatment options, often because drug development for small patient populations can be commercially challenging. We aim to bridge the gap between advancements in genetic science and meaningful medicines for underserved patient populations. Our decentralized, hub-and-spoke model is designed for speed, precision, and scalability. Autonomous and empowered teams focus on individual conditions, while a central hub provides the clinical, regulatory, and commercial capabilities needed to bring innovation to market. For more information, visit bridgebio.com and follow us on LinkedIn, X, Facebook, Instagram, YouTube, and TikTok.

BridgeBio Media Contact:
Bubba Murarka, Executive Vice President
contact@bridgebio.com  
(650)-789-8220

BridgeBio Investor Contact:
Chinmay Shukla, Senior Vice President, Strategic Finance
ir@bridgebio.com

FAQ

When will BridgeBio (BBIO) present at the BofA Health Care Conference in 2026?

BridgeBio will present at the BofA Health Care Conference on May 12, 2026 at 2:20 pm PDT. According to the company, management will participate in a fireside chat and the session will be webcast via the company’s Events and Presentations page.

How can investors watch BridgeBio (BBIO) presentations at the May–June 2026 conferences?

Investors can watch live webcasts on the company’s Events and Presentations investor page. According to the company, each presentation will be streamed live and a replay will be posted on the BridgeBio website for 90 days after the event.

What time is BridgeBio (BBIO) scheduled to speak at the Jefferies Global Healthcare Conference?

BridgeBio is scheduled at the Jefferies Global Healthcare Conference on June 4, 2026 at 11:05 am EDT. According to the company, members of management will appear in a fireside chat format and the session will be webcast for investors.

Will the Goldman Sachs presentation by BridgeBio (BBIO) be available after June 9, 2026?

Yes. According to the company, the Goldman Sachs presentation on June 9, 2026 at 8:00 am EDT will be webcast live and a replay will remain available on the BridgeBio website for 90 days following the event.

Which BridgeBio (BBIO) management forum type is scheduled at the May–June 2026 conferences?

BridgeBio management will participate in fireside chats at the listed conferences. According to the company, these are moderated discussion formats and will be accessible live via the company’s investor Events and Presentations webcasts.

Where on the BridgeBio website can I find the live webcast and replay for BBIO conference presentations?

Live webcasts and replays are available on the company’s Events and Presentations page in the Investors section. According to the company, replay recordings will be posted and remain online for 90 days after each event.